

Serge Gauthier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9227016/publications.pdf>

Version: 2024-02-01

223
papers

30,889
citations

21215

62
h-index

5481

169
g-index

247
all docs

247
docs citations

247
times ranked

28115
citing authors

#	ARTICLE	IF	CITATIONS
1	Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 207-219.	1.4	44
2	Impact of long- and short-range fibre depletion on the cognitive deficits of fronto-temporal dementia. <i>ELife</i> , 2022, 11, .	2.8	7
3	Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease. <i>EBioMedicine</i> , 2022, 76, 103836.	2.7	65
4	Comparing tau status determined via plasma pTau181, pTau231 and [18F]MK6240 tau-PET. <i>EBioMedicine</i> , 2022, 76, 103837.	2.7	34
5	Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia. <i>Alzheimer's and Dementia</i> , 2022, 18, 1408-1423.	0.4	24
6	Therapeutic Targets for Alzheimer's Disease: Amyloid Vs. Non-Amyloid. Where Does Consensus Lie Today? An CTAD Task Force Report. <i>Journal of prevention of Alzheimer's disease</i> , The, 2022, 9, 231-235.	1.5	2
7	Association of locus coeruleus integrity with Braak stage and neuropsychiatric symptom severity in Alzheimer's disease. <i>Neuropsychopharmacology</i> , 2022, 47, 1128-1136.	2.8	30
8	Staging of Alzheimer's disease: past, present, and future perspectives. <i>Trends in Molecular Medicine</i> , 2022, 28, 726-741.	3.5	36
9	APOE ϵ 4 potentiates the relationship between amyloid- β 2 and tau pathologies. <i>Molecular Psychiatry</i> , 2021, 26, 5977-5988.	4.1	51
10	Amyloid and Tau Pathology Associations With Personality Traits, Neuropsychiatric Symptoms, and Cognitive Lifestyle in the Preclinical Phases of Sporadic and Autosomal Dominant Alzheimer's Disease. <i>Biological Psychiatry</i> , 2021, 89, 776-785.	0.7	30
11	Determining Amyloid- β 2 Positivity Using ¹⁸ F-AZD4694 PET Imaging. <i>Journal of Nuclear Medicine</i> , 2021, 62, 247-252.	2.8	65
12	Topographic Distribution of Amyloid- β 2, Tau, and Atrophy in Patients With Behavioral/Dysexecutive Alzheimer Disease. <i>Neurology</i> , 2021, 96, e81-e92.	1.5	31
13	Trajectories of decline on instrumental activities of daily living prior to dementia in persons with mild cognitive impairment. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 314-323.	1.3	22
14	Neuropsychiatric symptoms are early indicators of an upcoming metabolic decline in Alzheimer's disease. <i>Translational Neurodegeneration</i> , 2021, 10, 1.	3.6	23
15	The US Expert Panel on the Appropriate Use Recommendations of Aducanumab in Clinical Practice. <i>Journal of prevention of Alzheimer's disease</i> , The, 2021, 8, 1-1.	1.5	0
16	Association between regional tau pathology and neuropsychiatric symptoms in aging and dementia due to Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12154.	1.8	19
17	Open science datasets from PREVENT-AD, a longitudinal cohort of pre-symptomatic Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2021, 31, 102733.	1.4	42
18	Vascular Contributions to Neurodegeneration: Protocol of the COMPASS-ND Study. <i>Canadian Journal of Neurological Sciences</i> , 2021, , 1-8.	0.3	6

#	ARTICLE	IF	CITATIONS
19	Associations of AT(N) biomarkers with neuropsychiatric symptoms in preclinical Alzheimer's disease and cognitively unimpaired individuals. <i>Translational Neurodegeneration</i> , 2021, 10, 11.	3.6	17
20	Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 69.	3.0	34
21	Association of plasma P-tau181 with memory decline in non-demented adults. <i>Brain Communications</i> , 2021, 3, fcab136.	1.5	33
22	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. <i>Nature Medicine</i> , 2021, 27, 1187-1196.	15.2	182
23	Microglial activation and tau propagate jointly across Braak stages. <i>Nature Medicine</i> , 2021, 27, 1592-1599.	15.2	235
24	Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages. <i>Brain</i> , 2021, 144, 3517-3528.	3.7	47
25	Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, <i>APOE</i> ϵ 4, and Cognitive Impairment. <i>Neurology</i> , 2021, 96, e975-e985.	1.5	42
26	Amyloid-independent and amyloid-independent effects of Tau in individuals without dementia. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 2083-2092.	1.7	7
27	Tau load in the lingual gyrus impacts anxiety levels during the COVID-19 pandemic in participants of longitudinal observational studies in aging. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
28	Tau accumulation using [¹⁸ F]MK6240 PET is associated with increase in executive dysfunction in prodromal AD. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
29	Cognitive health mediates the effect of hippocampal volume on COVID-19-related knowledge or anxiety change during the COVID-19 pandemic. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
30	Suicidal ideation is common in autosomal dominant Alzheimer's disease at-risk persons. <i>International Journal of Geriatric Psychiatry</i> , 2020, 35, 60-68.	1.3	4
31	Dementia in China: epidemiology, clinical management, and research advances. <i>Lancet Neurology</i> , The, 2020, 19, 81-92.	4.9	412
32	Association of Apolipoprotein E ϵ 4 With Medial Temporal Tau Independent of Amyloid- β . <i>JAMA Neurology</i> , 2020, 77, 470.	4.5	154
33	Remote cognitive and behavioral assessment: Report of the Alzheimer Society of Canada Task Force on dementia care best practices for COVID-19. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12111.	1.2	63
34	18F-MK-6240 PET for early and late detection of neurofibrillary tangles. <i>Brain</i> , 2020, 143, 2818-2830.	3.7	147
35	Canadian Consensus Conference on Diagnosis and Treatment of Dementia (CCCDTD)5: Guidelines for management of vascular cognitive impairment. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12056.	1.8	23
36	CCCDTD5 recommendations on early and timely assessment of neurocognitive disorders using cognitive, behavioral, and functional scales. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12057.	1.8	9

#	ARTICLE	IF	CITATIONS
37	Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia. <i>Alzheimer's and Dementia</i> , 2020, 16, 1182-1195.	0.4	119
38	Impact of p-tau181 and p-tau217 levels on enrollment for randomized clinical trials and future use of anti-amyloid and anti-tau drugs. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 1211-1213.	1.4	5
39	CCCDTD5: research diagnostic criteria for Alzheimer's Disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12036.	1.8	3
40	Lessons Learnt from the Second Generation of Anti-Amyloid Monoclonal Antibodies Clinical Trials. <i>Dementia and Geriatric Cognitive Disorders</i> , 2020, 49, 334-348.	0.7	34
41	Monitoring disease pathophysiology longitudinally using multiparametric PET acquisitions: The McGill TRIAD cohort. <i>Alzheimer's and Dementia</i> , 2020, 16, e043982.	0.4	0
42	CCCDTD5: Individual and community-based psychosocial and other non-pharmacological interventions to support persons living with dementia and their caregivers. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12086.	1.8	8
43	NON-AMYLOID APPROACHES TO DISEASE MODIFICATION FOR ALZHEIMER'S DISEASE: AN EU/US CTAD TASK FORCE REPORT. <i>Journal of prevention of Alzheimer's disease</i> , The, 2020, 7, 1-6.	1.5	15
44	Mild behavioral impairment is associated with β -amyloid but not tau or neurodegeneration in cognitively intact elderly individuals. <i>Alzheimer's and Dementia</i> , 2020, 16, 192-199.	0.4	102
45	Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. <i>Lancet Neurology</i> , The, 2020, 19, 422-433.	4.9	668
46	A quadratic function of activation in individuals at risk of Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12139.	1.2	15
47	Pandemic Dementia Scarce Resource Allocation. <i>Canadian Geriatrics Journal</i> , 2020, 23, 260-262.	0.7	9
48	CCCDTD5: Clinical role of neuroimaging and liquid biomarkers in patients with cognitive impairment. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12098.	1.8	5
49	Frontotemporal dementia and COVID-19: Hypothesis generation and roadmap for future research. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12085.	1.8	4
50	The Comprehensive Assessment of Neurodegeneration and Dementia: Canadian Cohort Study. <i>Canadian Journal of Neurological Sciences</i> , 2019, 46, 499-511.	0.3	56
51	Two Year Outcomes, Cognitive and Behavioral Markers of Decline in Healthy, Cognitively Normal Older Persons with Global Deterioration Scale Stage 2 (Subjective Cognitive Decline with Impairment). <i>Journal of Alzheimer's Disease</i> , 2019, 67, 685-705.	1.2	9
52	Users' perspectives on medical assistance in dying for persons with dementia. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 905-905.	1.3	0
53	COMBINATION THERAPY FOR ALZHEIMER'S DISEASE: PERSPECTIVES OF THE EU/US CTAD TASK FORCE. <i>Journal of prevention of Alzheimer's disease</i> , The, 2019, 6, 1-5.	1.5	29
54	Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers. <i>Brain</i> , 2019, 142, 1063-1076.	3.7	122

#	ARTICLE	IF	CITATIONS
55	Disconnection Between Self-Reported and Objective Cognitive Impairment in Obstructive Sleep Apnea. <i>Journal of Clinical Sleep Medicine</i> , 2019, 15, 409-415.	1.4	17
56	The continuum of care for dementia: needs, resources and practice in China. <i>Journal of Global Health</i> , 2019, 9, 020321.	1.2	33
57	ICâ€Pâ€132: CORTICAL IRON DEPOSITION IN ALZHEIMER'S DISEASE CONTRASTS WITH AGEâ€RELATED SUBCORTICAL DEPOSITION. <i>Alzheimer's and Dementia</i> , 2019, 15, P108.	0.4	0
58	Rasagiline, a monoamine oxidase B inhibitor, reduces in vivo [18F]THK5351 uptake in progressive supranuclear palsy. <i>NeuroImage: Clinical</i> , 2019, 24, 102091.	1.4	21
59	ICâ€02â€02: LONGITUDINAL EVALUATION OF TAU PROPAGATION USING [¹⁸ F]MKâ€6240. <i>Alzheimer's and Dementia</i> , 2019, 15, P2.	0.4	0
60	ICâ€Pâ€070: ASSOCIATIONS BETWEEN PLASMA NFL AND BRAIN PET IN THE ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P64.	0.4	1
61	ICâ€Pâ€071: ASSOCIATIONS BETWEEN PLASMA NFL AND BRAIN ATROPHY IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P65.	0.4	0
62	ICâ€Pâ€072: LONGITUDINAL ASSOCIATIONS BETWEEN PLASMA NFL AND VOXELâ€BASED MORPHOMETRY IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P66.	0.4	0
63	Brain Metabolic Dysfunction in Early Neuropsychiatric Symptoms of Dementia. <i>Frontiers in Pharmacology</i> , 2019, 10, 1398.	1.6	17
64	The Consortium for the early identification of Alzheimer's diseaseâ€Quebec (CIMAâ€Q). <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 787-796.	1.2	21
65	Targeting Alzheimerâ€™s Disease at the Right Time and the Right Place: Validation of a Personalized Approach to Diagnosis and Treatment. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S23-S31.	1.2	11
66	CYP2C19 variant mitigates Alzheimer disease pathophysiology in vivo and postmortem. <i>Neurology: Genetics</i> , 2018, 4, e216.	0.9	8
67	Proximity to Parental Symptom Onset and Amyloid-Î² Burden in Sporadic Alzheimer Disease. <i>JAMA Neurology</i> , 2018, 75, 608.	4.5	19
68	Dementia clinical trial implications of mild behavioral impairment. <i>International Psychogeriatrics</i> , 2018, 30, 171-175.	0.6	55
69	Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimerâ€™s disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1021-1030.	3.3	24
70	Anosognosia predicts default mode network hypometabolism and clinical progression to dementia. <i>Neurology</i> , 2018, 90, e932-e939.	1.5	54
71	The cost of Alzheimer's disease in China and reâ€estimation of costs worldwide. <i>Alzheimer's and Dementia</i> , 2018, 14, 483-491.	0.4	404
72	MEMO+: Efficacy, Durability and Effect of Cognitive Training and Psychosocial Intervention in Individuals with Mild Cognitive Impairment. <i>Journal of the American Geriatrics Society</i> , 2018, 66, 655-663.	1.3	71

#	ARTICLE	IF	CITATIONS
73	Characterizing biomarker features of cognitively normal individuals with ventriculomegaly. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 12-21.	1.2	9
74	Treatment effects of <i>Ginkgo biloba</i> extract EGb 761 [®] on the spectrum of behavioral and psychological symptoms of dementia: meta-analysis of randomized controlled trials. <i>International Psychogeriatrics</i> , 2018, 30, 285-293.	0.6	72
75	Comparative effect of statins on the risk of incident Alzheimer disease. <i>Neurology</i> , 2018, 90, e179-e187.	1.5	32
76	Progress in transnational scientific and ethics review: Commentary on the proposal for a single North American review board for research on dementia. <i>Alzheimer's and Dementia</i> , 2018, 14, 115-116.	0.4	2
77	P3 [®] 096: THE SYNERGISTIC INTERACTION BETWEEN AMYLOID AND TAU DISRUPTS LOCAL AND GLOBAL RESTING STATE FMRI CONNECTIVITY. <i>Alzheimer's and Dementia</i> , 2018, 14, P1103.	0.4	0
78	The influence of language and culture on cognitive assessment tools in the diagnosis of early cognitive impairment and dementia. <i>Expert Review of Neurotherapeutics</i> , 2018, 18, 859-869.	1.4	29
79	Detection of mild cognitive impairment in middle-aged and older adults with obstructive sleep apnoea. <i>European Respiratory Journal</i> , 2018, 52, 1801137.	3.1	23
80	Optimal use of cholinergic drugs in Alzheimer's disease. <i>Brain</i> , 2018, 141, e68.	3.7	3
81	In vivo quantification of neurofibrillary tangles with [18F]MK-6240. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 74.	3.0	120
82	Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 80.	3.0	55
83	Clinical Meaningfulness of Biomarker Endpoints in Alzheimer's Disease Research. <i>Neuroinformatics</i> , 2018, 20, 235-248.	0.2	0
84	The Mild Behavioral Impairment Checklist (MBI-C): A Rating Scale for Neuropsychiatric Symptoms in Pre-Dementia Populations. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 929-938.	1.2	306
85	[18F]FDG PET signal is driven by astroglial glutamate transport. <i>Nature Neuroscience</i> , 2017, 20, 393-395.	7.1	232
86	Consensus-based recommendations for the management of rapid cognitive decline due to Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 592-597.	0.4	17
87	Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease. <i>Neurology</i> , 2017, 88, 1814-1821.	1.5	61
88	Brain perfusion during rapid-eye-movement sleep successfully identifies amnesic mild cognitive impairment. <i>Sleep Medicine</i> , 2017, 34, 134-140.	0.8	8
89	The prevalence and biomarkers characteristic of rapidly progressive Alzheimer's disease from the Alzheimer's Disease Neuroimaging Initiative database. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 107-113.	1.8	16
90	Research update on Alzheimer's disease and introduction to the Expert Review of Neurotherapeutics special issue. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 1-2.	1.4	2

#	ARTICLE	IF	CITATIONS
91	Synergistic interaction between amyloid and tau predicts the progression to dementia. <i>Alzheimer's and Dementia</i> , 2017, 13, 644-653.	0.4	79
92	Identifying incipient dementia individuals using machine learning and amyloid imaging. <i>Neurobiology of Aging</i> , 2017, 59, 80-90.	1.5	85
93	Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 25.	3.0	285
94	[P3â€“321]: IN VIVO AND IN VITRO DEMONSTRATION OF [¹⁸ F]THK5351 BINDING TO MONOAMINE OXIDASEâ€“B IN THE HUMAN BRAIN. <i>Alzheimer's and Dementia</i> , 2017, 13, P1071.	0.4	0
95	[P3â€“436]: NATURAL HISTORY OF THE DECLINE IN INSTRUMENTAL ACTIVITIES OF DAILY LIVING PRIOR TO DEMENTIA IN PERSONS WITH MILD COGNITIVE IMPAIRMENT. <i>Alzheimer's and Dementia</i> , 2017, 13, P1136.	0.4	2
96	[P4â€“050]: GRAPHâ€“THEORY ANALYSIS SHOWS A HIGHLY EFFICIENT BUT REDUNDANT NETWORK IN MCI TAU PROPAGATION. <i>Alzheimer's and Dementia</i> , 2017, 13, P1275.	0.4	1
97	[P4â€“165]: CIMAâ€“Q: GENERAL OVERVIEW AND EARLY NEUROANATOMICAL FINDINGS IN SCD. <i>Alzheimer's and Dementia</i> , 2017, 13, P1325.	0.4	0
98	[P4â€“239]: FDGâ€“PET POWER TO PREDICT MEMORY DECLINE IN ALZHEIMER'S DISEASE DEPENDS ON DISEASE PHASE AND AMYLOID AND TAU STATUS. <i>Alzheimer's and Dementia</i> , 2017, 13, P1366.	0.4	0
99	[P1â€“149]: DATA SHARING POLICY AND CONSENT RECOMMENDATIONS IN DEMENTIA RESEARCH. <i>Alzheimer's and Dementia</i> , 2017, 13, P299.	0.4	0
100	[ICâ€“Pâ€“017]: VOXELâ€“WISE DETERMINATION OF SENSITIVITY, SPECIFICITY, AND THRESHOLDS FOR AMYLOID POSITIVITY USING [¹⁸ F]FLORBETAPIR PET. <i>Alzheimer's and Dementia</i> , 2017, 13, P20.	0.4	0
101	[ICâ€“Pâ€“034]: GRAPHâ€“THEORY ANALYSIS SHOWS A HIGHLY EFFICIENT BUT REDUNDANT NETWORK IN MCI TAU PROPAGATION. <i>Alzheimer's and Dementia</i> , 2017, 13, P30.	0.4	0
102	[ICâ€“Pâ€“045]: AMYLOIDâ€“BETA MODULATES CEREBRAL METABOLIC NETWORK IN RATS AND HUMANS. <i>Alzheimer's and Dementia</i> , 2017, 13, P38.	0.4	0
103	[P1â€“452]: COMBINED GLOBAL AND REGIONAL AMYLOID EFFECT ON THE DEFAULT MODE NETWORK LEADS TO COGNITIVE DECLINE. <i>Alzheimer's and Dementia</i> , 2017, 13, P459.	0.4	0
104	[P4â€“506]: COMPARISON BETWEEN MONOAMINE OXIDASE B INHIBITION ON THE UPTAKE OF [¹⁸ F]THK5351. <i>Alzheimer's and Dementia</i> , 2017, 13, P1533.	0.4	0
105	[P3â€“412]: PET TAU AND AMYLOID SYNERGISM WITHIN THE DEFAULT MODE NETWORK DETERMINES THE CLINICAL STATUS IN THE PREDEMENTIA PHASE OF ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P1123.	0.4	0
106	Dementia and Bioethics. <i>Mental Health and Illness Worldwide</i> , 2017, , 141-153.	0.1	0
107	Imaging Alzheimer's disease pathophysiology with PET. <i>Dementia E Neuropsychologia</i> , 2016, 10, 79-90.	0.3	33
108	VoxelStats: A MATLAB Package for Multi-Modal Voxel-Wise Brain Image Analysis. <i>Frontiers in Neuroinformatics</i> , 2016, 10, 20.	1.3	73

#	ARTICLE	IF	CITATIONS
109	ICâ€Pâ€027: Amyloidâ€Induced Microglial Activity in Thalamocortical Circuits Predicts Subsequent Cognitive Decline. Alzheimer's and Dementia, 2016, 12, P28.	0.4	0
110	P1â€251: Synergism between Brain Amyloid Accumulation and Neuronal Injury in Corticalâ€Subcortical Circuits Causes Memory Declines in Animal Models. Alzheimer's and Dementia, 2016, 12, P504.	0.4	0
111	ICâ€Pâ€099: Synergism Between Brain Amyloid Accumulation and Neuronal Injury in Corticalâ€Subcortical Circuits Causes Memory Declines in Animal Models. Alzheimer's and Dementia, 2016, 12, P75.	0.4	0
112	IC-P-101: Synergism Between Baseline Amyloidosis and Neuronal Injury as Determinants of Learning Deficits in AD Transgenic Rat Model. , 2016, 12, P77-P77.		0
113	O4â€08â€02: Phase 3 Trial of the TAU Aggregation Inhibitor Leucoâ€Methylthioniniumâ€Bis (Hydromethanesulfonate) (Lmtm) in Mild to Moderate Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P351.	0.4	3
114	P2-053: Amyloid-Induced Microglial Activity in Thalamocortical Circuits Predicts Subsequent Cognitive Decline. , 2016, 12, P627-P628.		0
115	Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet, The, 2016, 388, 2873-2884.	6.3	299
116	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimer's and Dementia, 2016, 12, 292-323.	0.4	1,318
117	Why has therapy development for dementia failed in the last two decades?. Alzheimer's and Dementia, 2016, 12, 60-64.	0.4	194
118	COMBINATION THERAPY OF ANTI-TAU AND ANTI-AMYLOID DRUGS FOR DISEASE MODIFICATION IN EARLY-STAGE ALZHEIMERâ€™S DISEASE: SOCIO-ECONOMIC CONSIDERATIONS MODELED ON TREATMENTS FOR TUBERCULOSIS, HIV/AIDS AND BREAST CANCER. journal of prevention of Alzheimer's disease, The, 2016, 3, 1-9.	1.5	14
119	Dementia and Bioethics. Mental Health and Illness Worldwide, 2016, , 1-13.	0.1	0
120	Epistasis analysis links immune cascades and cerebral amyloidosis. Journal of Neuroinflammation, 2015, 12, 227.	3.1	10
121	Patterns of Cognitive Decline Prior to Dementia in Persons with Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2015, 47, 901-913.	1.2	74
122	Measuring the impact of cognitive and psychosocial interventions in persons with mild cognitive impairment with a randomized single-blind controlled trial: rationale and design of the MEMO+ study. International Psychogeriatrics, 2015, 27, 511-525.	0.6	20
123	Le diagnostic prÃ©coce de la maladie dâ€™Alzheimer: panacÃ©e ou catastrophe?. Ethics, Medicine and Public Health, 2015, 1, 151-154.	0.5	2
124	Recommendations for the use of Serious Games in people with Alzheimer's Disease, related disorders and frailty. Frontiers in Aging Neuroscience, 2014, 6, 54.	1.7	155
125	Imaging biomarkers for amyloid: a new generation of probes and what lies ahead. International Psychogeriatrics, 2014, 26, 703-707.	0.6	2
126	Predicting decline in mild cognitive impairment: A prospective cognitive study.. Neuropsychology, 2014, 28, 643-652.	1.0	47

#	ARTICLE	IF	CITATIONS
127	Developments in Tau PET Imaging. Canadian Journal of Neurological Sciences, 2014, 41, 547-553.	0.3	45
128	Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurology, The, 2014, 13, 614-629.	4.9	2,657
129	Recollection and Familiarity in Aging Individuals with Mild Cognitive Impairment and Alzheimer's Disease: A Literature Review. Neuropsychology Review, 2014, 24, 313-331.	2.5	63
130	Tracking neuroinflammation in Alzheimer's disease: the role of positron emission tomography imaging. Journal of Neuroinflammation, 2014, 11, 120.	3.1	89
131	Plasma proteins predict conversion to dementia from prodromal disease. Alzheimer's and Dementia, 2014, 10, 799.	0.4	180
132	Use of amyloid PET across the spectrum of Alzheimer's disease: clinical utility and associated ethical issues. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2014, 21, 143-148.	1.4	28
133	Resting State Executive Control Network Adaptations in Amnesic Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2014, 40, 993-1004.	1.2	36
134	Donepezil-Associated Mania in Two Patients Who Were Using Donepezil Without a Prescription. Journal of Clinical Psychopharmacology, 2014, 34, 753-755.	0.7	6
135	P4-192: CEREBROLYSIN IN MILD TO MODERATE ALZHEIMER'S DISEASE: A META-ANALYSIS OF RANDOMIZED CONTROLLED CLINICAL TRIALS. , 2014, 10, P859-P859.		3
136	Executive functions in mild cognitive impairment: Emergence and breakdown of neural plasticity. Cortex, 2013, 49, 1268-1279.	1.1	71
137	A 10-year perspective on donepezil. Expert Opinion on Pharmacotherapy, 2013, 14, 331-338.	0.9	37
138	Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-to-severe Alzheimer's disease. Alzheimer's and Dementia, 2013, 9, 326-331.	0.4	90
139	Disclosure of results to participants in dementia research. Nature Reviews Neurology, 2013, 9, 608-609.	4.9	3
140	A randomized, double-blind, placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer's disease. International Psychogeriatrics, 2013, 25, 919-927.	0.6	51
141	Real-life effectiveness and tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease: the EMBRACE study. Current Medical Research and Opinion, 2013, 29, 989-1000.	0.9	15
142	The utility of the new research diagnostic criteria for Alzheimer's disease. International Psychogeriatrics, 2013, 25, 175-177.	0.6	14
143	White Matter Abnormalities and Structural Hippocampal Disconnections in Amnesic Mild Cognitive Impairment and Alzheimer's Disease. PLoS ONE, 2013, 8, e74776.	1.1	28
144	Executive function deficits in persons with mild cognitive impairment: A study with a Tower of London task. Journal of Clinical and Experimental Neuropsychology, 2012, 34, 306-324.	0.8	41

#	ARTICLE	IF	CITATIONS
145	Early-Onset Familial Alzheimer's Disease (EOFAD). Canadian Journal of Neurological Sciences, 2012, 39, 436-445.	0.3	160
146	Prevention strategies for Alzheimer's disease. Translational Neurodegeneration, 2012, 1, 13.	3.6	21
147	Recommendations of the 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD4). Canadian Geriatrics Journal, 2012, 15, 120-126.	0.7	114
148	Dissociation between Brain Amyloid Deposition and Metabolism in Early Mild Cognitive Impairment. PLoS ONE, 2012, 7, e47905.	1.1	47
149	Use of Biomarkers in Clinical Trials of Alzheimer Disease. Molecular Diagnosis and Therapy, 2011, 15, 313-325.	1.6	20
150	Prevention trials in Alzheimer's disease: An EU-US task force report. Progress in Neurobiology, 2011, 95, 594-600.	2.8	62
151	Alzheimer's disease. Lancet, The, 2011, 377, 1019-1031.	6.3	2,051
152	The nature of episodic memory deficits in MCI with and without vascular burden. Neuropsychologia, 2011, 49, 3027-3035.	0.7	37
153	Collaborative research between academia and industry using a large clinical trial database: a case study in Alzheimer's disease. Trials, 2011, 12, 233.	0.7	5
154	Switching cholinesterase inhibitors in older adults with dementia. International Psychogeriatrics, 2011, 23, 372-378.	0.6	30
155	Training-related brain plasticity in subjects at risk of developing Alzheimer's disease. Brain, 2011, 134, 1623-1634.	3.7	306
156	Effects of donepezil on activities of daily living: integrated analysis of patient data from studies in mild, moderate and severe Alzheimer's disease. International Psychogeriatrics, 2010, 22, 973-983.	0.6	37
157	Diagnosis of Prodromal Alzheimer's Disease: Do You Really Want to Know?. Canadian Journal of Neurological Sciences, 2010, 37, 2-2.	0.3	2
158	The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's disease. Current Medical Research and Opinion, 2010, 26, 2441-2447.	0.9	25
159	Effects of rivastigmine on common symptomatology of Alzheimer's disease (EXPLORE). Current Medical Research and Opinion, 2010, 26, 1149-1160.	0.9	27
160	Management of behavioral problems in Alzheimer's disease. International Psychogeriatrics, 2010, 22, 346-372.	0.6	295
161	Predicting cognitive decline in Alzheimer's disease: An integrated analysis. Alzheimer's and Dementia, 2010, 6, 431-439.	0.4	34
162	Priorities for research consortia on Alzheimer's disease. , 2010, 6, 359-362.		6

#	ARTICLE	IF	CITATIONS
163	Methodological Issues in Primary Prevention Trials for Neurodegenerative Dementia. <i>Journal of Alzheimer's Disease</i> , 2009, 16, 235-270.	1.2	42
164	Single- and Multiple-Domain Amnesic Mild Cognitive Impairment: Two Sides of the Same Coin. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 28, 541-549.	0.7	67
165	Ethics Issues with Private Research Ethics Boards: A Breakout Session at the 2009 NCEHR National Conference. <i>Journal of Academic Ethics</i> , 2009, 7, 69-73.	1.5	0
166	The assessment of recognition memory using the Remember/Know procedure in amnesic mild cognitive impairment and probable Alzheimer's disease. <i>Brain and Cognition</i> , 2009, 70, 171-179.	0.8	79
167	Management of agitation and aggression associated with Alzheimer disease. <i>Nature Reviews Neurology</i> , 2009, 5, 245-255.	4.9	336
168	Commentary on "A roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Who may benefit from disease-modifying studies in Alzheimer's disease?. , 2009, 5, 147-148.		0
169	Can we do better in developing new drugs for Alzheimer's disease?. <i>Alzheimer's and Dementia</i> , 2009, 5, 489-491.	0.4	25
170	TOP CITED PAPERS IN INTERNATIONAL PSYCHOGERIATRICS: 3. EFFICACY OF DONEPEZIL ON BEHAVIORAL SYMPTOMS IN PATIENTS WITH MODERATE TO SEVERE ALZHEIMER'S DISEASE. <i>International Psychogeriatrics</i> , 2009, 21, 454.	0.6	0
171	Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis. <i>International Journal of Geriatric Psychiatry</i> , 2008, 23, 537-545.	1.3	194
172	Revised research diagnostic criteria for Alzheimer's disease. <i>Lancet Neurology</i> , The, 2008, 7, 668-670.	4.9	21
173	Task switching capacities in persons with Alzheimer's disease and mild cognitive impairment. <i>Neuropsychologia</i> , 2008, 46, 2225-2233.	0.7	87
174	Symptomatic Therapeutic Aspects in Alzheimer's Disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 89, 269-271.	1.0	0
175	Current and future management of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2008, 4, S48-50.	0.4	10
176	A roadmap for the prevention of dementia: The inaugural Leon Thal Symposium. <i>Alzheimer's and Dementia</i> , 2008, 4, 156-163.	0.4	42
177	Cognitive complaint in mild cognitive impairment and Alzheimer's disease. <i>Journal of the International Neuropsychological Society</i> , 2008, 14, 222-32.	1.2	93
178	Current evidence for subjective cognitive impairment (SCI) as the pre-mild cognitive impairment (MCI) stage of subsequently manifest Alzheimer's disease. <i>International Psychogeriatrics</i> , 2008, 20, 1-16.	0.6	259
179	The association between depressive and cognitive symptoms in amnesic mild cognitive impairment. <i>International Psychogeriatrics</i> , 2008, 20, 710-723.	0.6	40
180	Pharmacotherapy of Alzheimer Disease. <i>Canadian Journal of Psychiatry</i> , 2007, 52, 620-629.	0.9	30

#	ARTICLE	IF	CITATIONS
181	Outcomes for Assessment of Symptomatic and Stabilization/Disease Modifying Drugs. Canadian Journal of Neurological Sciences, 2007, 34, S23-S26.	0.3	1
182	Clinical practice guidelines for severe Alzheimer's disease. Alzheimer's and Dementia, 2007, 3, 385-397.	0.4	51
183	EXACT: rivastigmine improves the high prevalence of attention deficits and mood and behaviour symptoms in Alzheimer's disease*. International Journal of Clinical Practice, 2007, 61, 886-895.	0.8	29
184	Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurology, The, 2007, 6, 734-746.	4.9	3,755
185	Trial Designs and Outcomes to Monitor Novel Therapeutics in Alzheimer's Disease. , 2007, , 28-35.		0
186	Mild cognitive impairment. Lancet, The, 2006, 367, 1262-1270.	6.3	2,401
187	Aggressive course of disease in dementia. , 2006, 2, 210-217.		45
188	PROGRESS IN CLINICAL NEUROSCIENCES: Canadian Guidelines for the Development of Antidementia Therapies: A Conceptual Summary. Canadian Journal of Neurological Sciences, 2006, 33, 6-26.	0.3	17
189	A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD:the EXTEND Study. Current Medical Research and Opinion, 2006, 22, 2251-2265.	0.9	22
190	Current and future therapies for Alzheimer's disease and related disorders. Future Neurology, 2006, 1, 741-745.	0.9	0
191	Improvement of Episodic Memory in Persons with Mild Cognitive Impairment and Healthy Older Adults: Evidence from a Cognitive Intervention Program. Dementia and Geriatric Cognitive Disorders, 2006, 22, 486-499.	0.7	338
192	Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial. International Journal of Geriatric Psychiatry, 2005, 20, 559-569.	1.3	105
193	Mild Cognitive Impairment Is Not a Clinical Entity and Should Not Be Treated. Archives of Neurology, 2005, 62, 1164.	4.9	90
194	Drugs for Alzheimer's disease and related dementias. BMJ: British Medical Journal, 2005, 330, 857-858.	2.4	10
195	Mild Cognitive Impairment Can Be Distinguished From Alzheimer Disease and Normal Aging for Clinical Trials. Archives of Neurology, 2004, 61, 59.	4.9	853
196	Pharmacotherapy of mild cognitive impairment. Dialogues in Clinical Neuroscience, 2004, 6, 391-395.	1.8	17
197	Vascular cognitive impairment. Lancet Neurology, The, 2003, 2, 89-98.	4.9	1,130
198	Efficacy of Donepezil on Maintenance of Activities of Daily Living in Patients with Moderate to Severe Alzheimer's Disease and the Effect on Caregiver Burden. Journal of the American Geriatrics Society, 2003, 51, 737-744.	1.3	189

#	ARTICLE	IF	CITATIONS
199	Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors. <i>Current Medical Research and Opinion</i> , 2003, 19, 707-714.	0.9	89
200	Does Vascular MCI Progress at a Different Rate Than Does Amnesic MCI?. <i>International Psychogeriatrics</i> , 2003, 15, 257-259.	0.6	12
201	Efficacy of Donepezil on Behavioral Symptoms in Patients With Moderate to Severe Alzheimer's Disease. <i>International Psychogeriatrics</i> , 2002, 14, 389-404.	0.6	211
202	Functional, Cognitive and Behavioral Effects of Donepezil in Patients with Moderate Alzheimer's Disease. <i>Current Medical Research and Opinion</i> , 2002, 18, 347-354.	0.9	78
203	Current and future therapeutic strategies for Alzheimer's disease and related dementias. <i>Expert Review of Neurotherapeutics</i> , 2002, 2, 277-278.	1.4	1
204	Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. <i>Lancet, The</i> , 2002, 359, 1283-1290.	6.3	712
205	Advances in the pharmacotherapy of Alzheimer's disease. <i>Cmaj</i> , 2002, 166, 616-23.	0.9	17
206	Cholinergic Adverse Effects of Cholinesterase Inhibitors in Alzheimer's Disease. <i>Drugs and Aging</i> , 2001, 18, 853-862.	1.3	79
207	Alzheimer's disease: current and future therapeutic perspectives. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2001, 25, 73-89.	2.5	25
208	Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success?. <i>International Journal of Geriatric Psychiatry</i> , 2001, 16, 653-666.	1.3	110
209	Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial - Commentary: Another piece of the Alzheimer's jigsaw. <i>BMJ: British Medical Journal</i> , 1999, 318, 633-640.	2.4	782
210	Effects of Calyculin A and Okadaic Acid on Acetylcholine Release and Subcellular Distribution in Rat Hippocampal Formation. <i>Journal of Neurochemistry</i> , 1999, 72, 166-173.	2.1	12
211	Economic Evaluation of Donepezil for the Treatment of Alzheimer's Disease in Canada. <i>Journal of the American Geriatrics Society</i> , 1999, 47, 570-578.	1.3	107
212	Development of a Functional Measure for Persons With Alzheimer's Disease: The Disability Assessment for Dementia. <i>American Journal of Occupational Therapy</i> , 1999, 53, 471-481.	0.1	763
213	Prevalence and severity of cognitive impairment with and without dementia in an elderly population. <i>Lancet, The</i> , 1997, 349, 1793-1796.	6.3	893
214	Standardization of the Diagnosis of Dementia in the Canadian Study of Health and Aging. <i>Neuroepidemiology</i> , 1996, 15, 246-256.	1.1	126
215	Comparative ontogenic profile of cholinergic markers, including nicotinic and muscarinic receptors, in the rat brain. , 1996, 369, 31-55.		102
216	Effects of the Phosphatase Inhibitors Calyculin A and Okadaic Acid on Acetylcholine Synthesis and Content of Rat Hippocampal Formation. <i>Journal of Neurochemistry</i> , 1996, 66, 1924-1932.	2.1	21

#	ARTICLE	IF	CITATIONS
217	Spectral analysis of the rapid eye movement sleep electroencephalogram in right and left temporal regions: A biological marker of Alzheimer's disease. <i>Annals of Neurology</i> , 1992, 32, 172-176.	2.8	66
218	Neurochemical Deficits in Pathological Brain Aging: Specificity and Possible Relevance for Treatment Strategies. <i>Clinical Neuropharmacology</i> , 1990, 13, S73-S80.	0.2	25
219	Canadian Collaborative Study of Tetrahydroaminoacridine (THA) and Lecithin Treatment of Alzheimer's Disease: Effect on Mood. <i>Canadian Journal of Psychiatry</i> , 1989, 34, 165-170.	0.9	10
220	Paired helical filaments and the cytoplasmic-nuclear interface in Alzheimer's disease. <i>Journal of Neurocytology</i> , 1988, 17, 827-833.	1.6	51
221	Influx of a choline analog to dog brain measured by positron emission tomography. <i>Synapse</i> , 1988, 2, 406-411.	0.6	11
222	Effect of folic acid and vitamin B12 deficiencies on 5-hydroxyindoleacetic acid in human cerebrospinal fluid. <i>Annals of Neurology</i> , 1982, 12, 479-484.	2.8	96
223	The Origin of Indoleacetic Acid and Indolepropionic Acid in Rat and Human Cerebrospinal Fluid. <i>Journal of Neurochemistry</i> , 1980, 34, 1087-1092.	2.1	85